-
-
-
-
-
-
-
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
-
-
-
-
-
-
-
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
-
-
-
-
-
-
-
Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update
-
-
-
-
-
-
-
Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update
-
-
-
-
-
-
-
Chemomab Announces FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis
-
-
727 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

